Express News | Loews Corp Shares Hit Record High, Last up 1.3%

ReutersJul 18 10:54 ET

Loews (NYSE:L) Shareholders Have Earned a 7.6% CAGR Over the Last Five Years

Yahoo FinanceJul 12 12:33 ET

Citi Research's AI Hedge Stocks - Part I

Seeking AlphaJul 9 13:20 ET

Loews Corporation to Release Second Quarter 2024 Results on July 29, 2024

Loews Corporation (NYSE: L) will report second quarter 2024 financial results on Monday, July 29, 2024. On that date the Company will also post...

PR NewswireJul 9 10:00 ET

Should Weakness in Loews Corporation's (NYSE:L) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

With its stock down 2.9% over the past three months, it is easy to disregard Loews (NYSE:L). However, stock prices are usually driven by a company's financials over the long term, which in this case

Simply Wall StJul 5 06:33 ET

Hesen Biotech acquires 14 branded pharmaceuticals from Celltrion, enriching product pipeline in 8 countries.

On June 28th, Heisen Biotech Co., Ltd. (Heisen Biotech) announced that it has officially completed the acquisition of the commercial rights of 14 branded products under the South Korean biopharmaceutical company Celltrion in multiple countries and regions in the Asia-Pacific region, and holds the marketing authorization holder (MAH) rights for these products in eight countries and regions including South Korea (excluding Nexinavir, Yidabio and Aiketuo), Singapore, Thailand, Australia, and Hong Kong, China. It is reported that this acquisition will enrich the company's product pipeline in eight countries and regions outside of mainland China and establish a more complete international supply chain and quality system.

新浪科技Jun 28 05:11 ET